Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics has announced a positive outlook on its financial health, revealing tight cost management and strategic R&D spending that have extended its cash runway to late-October. The company also highlights that an additional £12.5 million in funding is accessible and hints at impending debt financing to bolster its operations and development activities. Investors can anticipate the company’s preliminary financial results for 2024 by the end of October, indicating a transparent approach to its fiscal updates.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
